, Tracking Stock Market Picks
Enter Symbol:
Auxilium Pharmaceuticals, Inc. (AUXL) [hlAlert]

down 8.88 %

Auxilium Pharmaceuticals, Inc. (AUXL) downgraded to Sell by FTN Equity Capital

Posted on: Wednesday,  Apr 1, 2009  9:25 AM ET by FTN Equity Capital

FTN Equity Capital rated Sell Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) on 04/01/2009. Previously FTN Equity Capital rated Buy Auxilium Pharmaceuticals, Inc. (NASDAQ:
AUXL) on 03/12/2009., when the stock price was $27.00. Since then, Auxilium Pharmaceuticals, Inc. has lost 8.89% as of 04/01/2009's recent price of $24.60.
If you would have followed the previous FTN Equity Capital 's recommendation on AUXL, you would have lost 8.88% of your investment in 20 days.

Auxilium Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets products for urology and sexual health. Auxilium markets Testim 1%, a topical testosterone gel, for the treatment of hypogonadism. Auxilium is developing additional Testim line extensions, as well as other products for urology and sexual health, including an enzyme in Phase II for the treatment of Peyronie's Disease that may also prove useful for the treatment of Dupuytren's Disease.

Having access to accurate and timely information is essential for success in today's marketplace. At FTN Equity Capital Markets, our focus is on providing thorough and objective research to our clients, empowering them to make the well-informed and educated decisions that help enhance their investment process. Our highly experienced team of analytical experts research, examine, and evaluate businesses in several markets, including consumer, health care, business and technology services, and financial service sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/1/2009 9:25 AM Sell
as of 12/31/2009
1 Week up  26.87 %
1 Month up  36.16 %
3 Months up  34.93 %
1 YTD up  0.63 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/12/2009 9:25 AM Buy

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy